Somatic Mutations of the Immunoglobulin Framework Are Generally Required for Broad and Potent HIV-1 Neutralization

Broadly neutralizing antibodies (bNAbs) to HIV-1 can prevent infection and are therefore of great importance for HIV-1 vaccine design. Notably, bNAbs are highly somatically mutated and generated by a fraction of HIV-1-infected individuals several years after infection. Antibodies typically accumulate mutations in the complementarity determining region (CDR) loops, which usually contact the antigen. The CDR loops are scaffolded by canonical framework regions (FWRs) that are both resistant to and less tolerant of mutations. Here, we report that in contrast to most antibodies, including those with limited HIV-1 neutralizing activity, most bNAbs require somatic mutations in their FWRs. Structural and functional analyses reveal that somatic mutations in FWR residues enhance breadth and potency by providing increased flexibility and/or direct antigen contact. Thus, in bNAbs, FWRs play an essential role beyond scaffolding the CDR loops and their unusual contribution to potency and breadth should be considered in HIV-1 vaccine design.

[1]  C. Milstein,et al.  Kinetic maturation of an immune response , 1991, Nature.

[2]  Richard T. Wyatt,et al.  Breadth of Human Immunodeficiency Virus-Specific Neutralizing Activity in Sera: Clustering Analysis and Association with Clinical Variables , 2009, Journal of Virology.

[3]  J. Weill,et al.  Hypermutation generating the sheep immunoglobulin repertoire is an antigen-independent process , 1995, Cell.

[4]  K. Rajewsky Clonal selection and learning in the antibody system , 1996, Nature.

[5]  N. Haigwood,et al.  Neutralizing antibody directed against the HIV–1 envelope glycoprotein can completely block HIV–1/SIV chimeric virus infections of macaque monkeys , 1999, Nature Medicine.

[6]  Holly Janes,et al.  Tiered Categorization of a Diverse Panel of HIV-1 Env Pseudoviruses for Assessment of Neutralizing Antibodies , 2009, Journal of Virology.

[7]  M. Nussenzweig,et al.  Autoreactivity in human IgG+ memory B cells. , 2007, Immunity.

[8]  Yan Liu,et al.  A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield , 2011, Science.

[9]  Martin A. Nowak,et al.  Antibody neutralization and escape by HIV-1 , 2003, Nature.

[10]  P. T. Jones,et al.  Replacing the complementarity-determining regions in a human antibody with those from a mouse , 1986, Nature.

[11]  R L Stanfield,et al.  Crystal structures of an antibody to a peptide and its complex with peptide antigen at 2.8 A. , 1992, Science.

[12]  D. Burton,et al.  Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo , 2012, Proceedings of the National Academy of Sciences.

[13]  Bette Korber,et al.  Structure of a V3-Containing HIV-1 gp120 Core , 2005, Science.

[14]  F. Pereyra,et al.  A method for identification of HIV gp140 binding memory B cells in human blood. , 2009, Journal of immunological methods.

[15]  M. Neuberger,et al.  Affinity dependence of the B cell response to antigen: a threshold, a ceiling, and the importance of off-rate. , 1998, Immunity.

[16]  Q. Sattentau,et al.  Analysis of Memory B Cell Responses and Isolation of Novel Monoclonal Antibodies with Neutralizing Breadth from HIV-1-Infected Individuals , 2010, PloS one.

[17]  Richard T. Wyatt,et al.  Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals , 2009, Nature.

[18]  D. Burton,et al.  Very Few Substitutions in a Germ Line Antibody Are Required To Initiate Significant Domain Exchange , 2010, Journal of Virology.

[19]  C. Milstein,et al.  Codon bias targets mutation , 1995, Nature.

[20]  D. Burton,et al.  Rapid development of glycan-specific, broad, and potent anti–HIV-1 gp120 neutralizing antibodies in an R5 SIV/HIV chimeric virus infected macaque , 2011, Proceedings of the National Academy of Sciences.

[21]  Marie-Paule Lefranc,et al.  IMGT, the international ImMunoGeneTics database. , 1997, Nucleic acids research.

[22]  Baoshan Zhang,et al.  Broad and potent neutralization of HIV-1 by a gp41-specific human antibody , 2012, Nature.

[23]  R. Poljak,et al.  Three-dimensional structure of immunoglobulins. , 1979, Annual review of biochemistry.

[24]  Ron Diskin,et al.  HIV therapy by a combination of broadly neutralizing antibodies in humanized mice , 2012, Nature.

[25]  P. Emsley,et al.  Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.

[26]  Tongqing Zhou,et al.  Structural Basis of Immune Evasion at the Site of CD4 Attachment on HIV-1 gp120 , 2009, Science.

[27]  Lynn Morris,et al.  Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein , 2012, The Journal of experimental medicine.

[28]  Tongqing Zhou,et al.  Structural definition of a conserved neutralization epitope on HIV-1 gp120 , 2007, Nature.

[29]  Mario Roederer,et al.  Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1 , 2010, Science.

[30]  M. Luftig,et al.  Structural basis for HIV-1 neutralization by a gp41 fusion intermediate–directed antibody , 2006, Nature Structural &Molecular Biology.

[31]  S. Zolla-Pazner,et al.  Structural basis of the cross-reactivity of genetically related human anti-HIV-1 mAbs: implications for design of V3-based immunogens. , 2009, Structure.

[32]  Mario Roederer,et al.  Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing , 2011, Science.

[33]  Michael S. Seaman,et al.  Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies , 2012, Proceedings of the National Academy of Sciences.

[34]  Randy J. Read,et al.  Phaser crystallographic software , 2007, Journal of applied crystallography.

[35]  Peter D. Kwong,et al.  Structure and Mechanistic Analysis of the Anti-Human Immunodeficiency Virus Type 1 Antibody 2F5 in Complex with Its gp41 Epitope , 2004, Journal of Virology.

[36]  A. Trkola,et al.  Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. , 1994, AIDS research and human retroviruses.

[37]  D. Montefiori,et al.  Evaluating Neutralizing Antibodies Against HIV, SIV, and SHIV in Luciferase Reporter Gene Assays , 2004, Current protocols in immunology.

[38]  S. Zolla-Pazner,et al.  Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120. , 1993, Journal of immunology.

[39]  Xiping Wei,et al.  Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies , 2005, Journal of Virology.

[40]  Tongqing Zhou,et al.  Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01 , 2010, Science.

[41]  Maxim N. Artyomov,et al.  Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation , 2010, Nature.

[42]  Ron Diskin,et al.  Increasing the Potency and Breadth of an HIV Antibody by Using Structure-Based Rational Design , 2011, Science.

[43]  M. Nussenzweig,et al.  Human anti–HIV-neutralizing antibodies frequently target a conserved epitope essential for viral fitness , 2010, The Journal of experimental medicine.

[44]  J. Mascola,et al.  Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies , 2000, Nature Medicine.

[45]  S. Zolla-Pazner,et al.  Crystal Structures of Human Immunodeficiency Virus Type 1 (HIV-1) Neutralizing Antibody 2219 in Complex with Three Different V3 Peptides Reveal a New Binding Mode for HIV-1 Cross-Reactivity , 2006, Journal of Virology.

[46]  Sergio Roa,et al.  The biochemistry of somatic hypermutation. , 2008, Annual review of immunology.

[47]  Young Do Kwon,et al.  Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility , 2009, Proceedings of the National Academy of Sciences.

[48]  Wolfgang Kabsch,et al.  Integration, scaling, space-group assignment and post-refinement , 2010, Acta crystallographica. Section D, Biological crystallography.

[49]  R. Poljak,et al.  Three-dimensional structure of an antigen-antibody complex at 2.8 A resolution , 1986, Science.

[50]  M. Nussenzweig,et al.  Memory B Cell Antibodies to HIV-1 gp140 Cloned from Individuals Infected with Clade A and B Viruses , 2011, PloS one.

[51]  C. H. Bell,et al.  Structure of antibody F425-B4e8 in complex with a V3 peptide reveals a new binding mode for HIV-1 neutralization. , 2008, Journal of molecular biology.

[52]  Ping Zhu,et al.  Antibody Domain Exchange Is an Immunological Solution to Carbohydrate Cluster Recognition , 2003, Science.

[53]  T. Kepler,et al.  Isolation of a Human Anti-HIV gp41 Membrane Proximal Region Neutralizing Antibody by Antigen-Specific Single B Cell Sorting , 2011, PloS one.

[54]  G Himmler,et al.  A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1 , 1993, Journal of virology.

[55]  Pham Phung,et al.  Broad neutralization coverage of HIV by multiple highly potent antibodies , 2011, Nature.

[56]  Ron Diskin,et al.  Structure of a clade C HIV-1 gp120 bound to CD4 and CD4-induced antibody reveals anti-CD4 polyreactivity , 2010, Nature Structural &Molecular Biology.

[57]  Ian A Wilson,et al.  Structural basis of enhanced binding of extended and helically constrained peptide epitopes of the broadly neutralizing HIV-1 antibody 4E10. , 2007, Journal of molecular biology.

[58]  D. Dimitrov,et al.  Maturation Pathways of Cross-Reactive HIV-1 Neutralizing Antibodies , 2009, Viruses.

[59]  Randy J. Read,et al.  Acta Crystallographica Section D Biological , 2003 .

[60]  Pham Phung,et al.  Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target , 2009, Science.

[61]  Peter D. Kwong,et al.  Structures of the CCR5 N Terminus and of a Tyrosine-Sulfated Antibody with HIV-1 gp120 and CD4 , 2007, Science.

[62]  Robyn L Stanfield,et al.  Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D. , 2004, Structure.

[63]  M. Nussenzweig,et al.  AID targeting in antibody diversity. , 2011, Advances in immunology.

[64]  David G. Schatz,et al.  Targeting of somatic hypermutation , 2006, Nature Reviews Immunology.

[65]  Terri Wrin,et al.  Human Immunodeficiency Virus Type 1 Elite Neutralizers: Individuals with Broad and Potent Neutralizing Activity Identified by Using a High-Throughput Neutralization Assay together with an Analytical Selection Algorithm , 2009, Journal of Virology.

[66]  Young Do Kwon,et al.  Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9 , 2011, Nature.

[67]  Virginia Pascual,et al.  Somatic Hypermutation Introduces Insertions and Deletions into Immunoglobulin V Genes , 1998, The Journal of experimental medicine.

[68]  Ron Diskin,et al.  Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding , 2011, Science.

[69]  G. Gonnet,et al.  Exhaustive matching of the entire protein sequence database. , 1992, Science.

[70]  T. T. Wu,et al.  AN ANALYSIS OF THE SEQUENCES OF THE VARIABLE REGIONS OF BENCE JONES PROTEINS AND MYELOMA LIGHT CHAINS AND THEIR IMPLICATIONS FOR ANTIBODY COMPLEMENTARITY , 1970, The Journal of experimental medicine.

[71]  E. Kabat,et al.  Sequences of proteins of immunological interest , 1991 .

[72]  Patrice Duroux,et al.  IMGT/LIGM-DB, the IMGT® comprehensive database of immunoglobulin and T cell receptor nucleotide sequences , 2005, Nucleic Acids Res..

[73]  J. Sodroski,et al.  Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding , 1993, Journal of virology.

[74]  D. Dimitrov,et al.  Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: Implications for evasion of immune responses and design of vaccine immunogens , 2009, Biochemical and Biophysical Research Communications.

[75]  A. Trkola,et al.  Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1 , 1996, Journal of virology.

[76]  M. Altfeld,et al.  Characteristics of the Earliest Cross-Neutralizing Antibody Response to HIV-1 , 2011, PLoS pathogens.